Larvol Delta - Coeptis-Therapeutics-Provides-Safety-and-Dosing-Update-from-Phase-1-Trials-Investigating-DVX201-in-RelapsedRefractory-AML-or-High-Risk-MDS-and-Hospitalized-COVID19-Infection

DVX201 - Coeptis

https://www.prnewswire.com/news-releases/coeptis-therapeutics-provides-safety-and-dosing-update-from-phase-1-trials-investigating-dvx201-in-relapsedrefractory-aml-or-high-risk-mds-and-hospitalized-covid-19-infection-301927462.html

Sep 14, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next